{"id":27060,"date":"2026-08-24T17:44:52","date_gmt":"2026-08-24T21:44:52","guid":{"rendered":"https:\/\/www.emilysentourage.org\/?p=27060"},"modified":"2026-08-24T17:44:52","modified_gmt":"2026-08-24T21:44:52","slug":"emilys-entourage-funds-novel-therapy-to-target-mrsa-lung-infections-in-cystic-fibrosis","status":"publish","type":"post","link":"https:\/\/www.emilysentourage.org\/tr\/emilys-entourage-funds-novel-therapy-to-target-mrsa-lung-infections-in-cystic-fibrosis\/","title":{"rendered":"Emily\u2019s Entourage, Kistik Fibroziste MRSA Akci\u011fer Enfeksiyonlar\u0131n\u0131 Hedefleyen Yeni Nesil Tedaviyi Finanse Ediyor"},"content":{"rendered":"

\u0130nhale vankomisin-DNaz kombinasyonu biyofilmlerin \u00fcstesinden gelmeyi ve kal\u0131c\u0131 MRSA enfeksiyonlar\u0131 i\u00e7in tedaviyi iyile\u015ftirmeyi ama\u00e7lamaktad\u0131r<\/span><\/i><\/p>\n

\"\"

Emily\u2019s Entourage (EE), 2026 y\u0131l\u0131ndaki \u00fc\u00e7\u00fcnc\u00fc \u00c7eviri Ara\u015ft\u0131rma Hibesinin, The University of Texas at Austin Eczac\u0131l\u0131k Fak\u00fcltesi'nden Molek\u00fcler Farmas\u00f6tik ve \u0130la\u00e7 Da\u011f\u0131t\u0131m\u0131 Alcon Centennial Profes\u00f6r\u00fc Dr. Hugh Smyth'e verildi\u011fini duyurdu.<\/p><\/div>\n

Lower Merion, PA \u2014 24 A\u011fustos 2026<\/span>\u2014Mevcut mutasyon odakl\u0131 tedavilerden yararlanamayan kistik fibroz (KF) hastalar\u0131 i\u00e7in ara\u015ft\u0131rmalar\u0131 h\u0131zland\u0131ran yenilik\u00e7i bir 501(c)(3) kurulu\u015fu olan Emily\u2019s Entourage (EE), bug\u00fcn \u00fc\u00e7\u00fcnc\u00fc<\/span>\u00a02026 \u00c7eviri Ara\u015ft\u0131rma Hibesi, UT Austin Eczac\u0131l\u0131k Fak\u00fcltesi Molek\u00fcler Eczac\u0131l\u0131k ve \u0130la\u00e7 Da\u011f\u0131t\u0131m\u0131 Alcon Centennial Profes\u00f6r\u00fc Do\u00e7. Dr. Hugh Smyth'e verilmi\u015ftir.<\/span><\/p>\n

Dr. Smyth's projesi, metisiline diren\u00e7li <\/span>Staphylococcus aureus<\/span><\/i> (MRSA) akci\u011fer enfeksiyonlar\u0131\u2014KF'li hastalar\u0131 etkileyen en kal\u0131c\u0131 ve tedbiri en zor enfeksiyonlardan biridir.<\/span><\/p>\n

Tedavi alan\u0131ndaki \u00f6nemli ilerlemelere ra\u011fmen, kronik akci\u011fer enfeksiyonlar\u0131 CF\u2019de h\u00e2l\u00e2 en \u00f6nemli hastal\u0131k ve \u00f6l\u00fcm nedenlerinden biridir. MRSA enfeksiyonlar\u0131, CF hastalar\u0131n\u0131n yakla\u015f\u0131k %'sini etkilemektedir ve MRSA enfeksiyonu olmayan bireylere k\u0131yasla % daha y\u00fcksek bir \u00f6l\u00fcm oran\u0131 ve ortalama alt\u0131 y\u0131ldan fazla bir ya\u015fam s\u00fcresi azalmas\u0131 dahil olmak \u00fczere, \u00f6nemli \u00f6l\u00e7\u00fcde daha k\u00f6t\u00fc klinik sonu\u00e7larla ili\u015fkilidir. <\/span><\/p>\n

Mevcut tedaviler genellikle vankomisin veya linezolid gibi sistemik antibiyotiklere dayanmaktad\u0131r; bu durum, enfeksiyon b\u00f6lgesinde de\u011fi\u015fken ila\u00e7 konsantrasyonlar\u0131na ve potansiyel sistemik toksisiteye yol a\u00e7abilir. Ek olarak, MRSA akci\u011fer enfeksiyonlar\u0131n\u0131n tedavisindeki en b\u00fcy\u00fck zorluklardan biri, bakterileri antibiyotiklerden ve ba\u011f\u0131\u015f\u0131kl\u0131k savunmas\u0131ndan koruyan yo\u011fun yap\u0131lar olan bakteriyel biyofilmlerin olu\u015fumudur. Bu biyofilmler ayn\u0131 zamanda tedaviden sa\u011f kurtulan ve kronik ile tekrarlayan enfeksiyonlara katk\u0131da bulunan \u201cal\u0131c\u0131\u201d (persister) h\u00fccreleri de bar\u0131nd\u0131rabilir.<\/span><\/p>\n

Bu zorlu\u011fun \u00fcstesinden gelmek i\u00e7in Dr. Smyth ve ekibi, yayg\u0131n olarak kullan\u0131lan bir MRSA kar\u015f\u0131t\u0131 antibiyotik olan vankomisini, biyofilm yap\u0131s\u0131n\u0131n par\u00e7alanmas\u0131na yard\u0131mc\u0131 olan bir enzim olan DNase I ile e\u015fle\u015ftiren yenilik\u00e7i, inhalasyon yoluyla uygulanan sabit dozlu bir kombinasyon tedavisi geli\u015ftirmi\u015ftir. Kistik fibrozis hastalar\u0131 taraf\u0131ndan mukusu inceltmek i\u00e7in halihaz\u0131rda kullan\u0131lan bir DNase tedavisi olan Pulmozyme\u00ae, bu enzim s\u0131n\u0131f\u0131n\u0131n bir \u00f6rne\u011fidir. DNase I, biyofilmi bozarak vankomisinin daha etkili bir \u015fekilde n\u00fcfuz etmesini ve kal\u0131c\u0131 h\u00fccreler de dahil olmak \u00fczere bakterileri ortadan kald\u0131rmas\u0131n\u0131 sa\u011flar.<\/span><\/p>\n

\u00d6n \u00e7al\u0131\u015fmalar, vankomisin ve DNaz I'in birlikte form\u00fcle edilmesinin ve e\u015f zamanl\u0131 uygulanmas\u0131n\u0131n MRSA biyofilmlerini etkili bir \u015fekilde yok etmek i\u00e7in kritik oldu\u011funu g\u00f6stermi\u015ftir. Buna kar\u015f\u0131l\u0131k, iki tedavinin ard\u0131\u015f\u0131k olarak uygulanmas\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde daha az etkiliydi.<\/span><\/p>\n

Ara\u015ft\u0131rma ekibi ayr\u0131ca, her iki etken maddenin do\u011frudan akci\u011ferlere iletilmesini sa\u011flayan, inhalasyon i\u00e7in tasarlanm\u0131\u015f y\u00fcksek dozlu, spreyle kurutulmu\u015f bir toz form\u00fclasyon geli\u015ftirmi\u015ftir. Bu hedeflenmi\u015f yakla\u015f\u0131m, sistemik maruziyeti en aza indirirken enfeksiyon b\u00f6lgesindeki ilac\u0131n konsantrasyonunu art\u0131rmay\u0131 ama\u00e7lamaktad\u0131r.<\/span><\/p>\n

\u00d6nerilen ara\u015ft\u0131rma, kistik fibrozisli bireylerden elde edilen klinik a\u00e7\u0131dan ilgili biyofilmlerin yan\u0131 s\u0131ra bir MRSA akci\u011fer enfeksiyonu hayvan modelinde inhale form\u00fclasyonu optimize edecek ve etkinli\u011fini de\u011ferlendirecektir. Bu \u00e7al\u0131\u015fmalar, hedeflenen bir inhale tedaviyi klinik geli\u015ftirmeye do\u011fru ilerletmeyi ama\u00e7lamaktad\u0131r.<\/span><\/p>\n

\u201cKistik fibrozis tedavisinde MRSA akci\u011fer enfeksiyonlar\u0131, kar\u015f\u0131lanmam\u0131\u015f \u00f6nemli bir ihtiya\u00e7 olmaya devam ediyor\u201d dedi Dr. Smyth. \u201cBiyofilm da\u011f\u0131t\u0131c\u0131 bir enzimi inhale bir antibiyotikle e\u015fle\u015ftirerek amac\u0131m\u0131z, mevcut yakla\u015f\u0131mlarla tedavisi zor olan bakterilere daha iyi ula\u015fmak ve onlar\u0131 ortadan kald\u0131rmak i\u00e7in tasarlanm\u0131\u015f hedefe y\u00f6nelik bir tedavi geli\u015ftirmektir.\u201d<\/span><\/p><\/blockquote>\n

\u201cEE Ba\u015f Bilim Sorumlusu Dr. Chandra Ghose, \u201dKal\u0131c\u0131 ve tedaviye diren\u00e7li enfeksiyonlar, kistik fibrozis (KF) hastalar\u0131 i\u00e7in, \u00f6zellikle de CFTR mod\u00fclat\u00f6rleri \u00e7a\u011f\u0131nda bile bu mod\u00fclat\u00f6rlerden yararlanamayanlar a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck bir zorluk olmaya devam ediyor,\u201c dedi ve ekledi: \u201dBiyofilmlerin \u00fcstesinden gelmek ve tedaviyi do\u011frudan akci\u011ferlere ula\u015ft\u0131rmak i\u00e7in tasarlanm\u0131\u015f bunun gibi yenilik\u00e7i yakla\u015f\u0131mlar\u0131 destekleyerek, daha etkili tedavi stratejilerinin ilerletilmesine yard\u0131mc\u0131 olmay\u0131 ve KF ile ya\u015fayanlar i\u00e7in se\u00e7enekleri geni\u015fletmeyi ama\u00e7l\u0131yoruz.\u201d<\/span><\/p>\n

Emily's Entourage'\u0131n (EE) Hibe Program\u0131 Hakk\u0131nda<\/b><\/p>\n

Emily's Entourage's (EE) Hibrit Program\u0131, mevcut mutasyon odakl\u0131 tedavilerden yararlanamayan kistik fibrozisli (KF) hastalar i\u00e7in ara\u015ft\u0131rmalar\u0131 ve terap\u00f6tik geli\u015ftirmeyi h\u0131zland\u0131rmak amac\u0131yla finansman sa\u011flamaktad\u0131r. EE; \u00e7eviri hibeleri, i\u015f birli\u011fi hibeleri ve klinik \u00f6ncesi ke\u015fif hibelerinin yan\u0131 s\u0131ra risk sermayesi hay\u0131rseverli\u011fi yat\u0131r\u0131mlar\u0131 dahil olmak \u00fczere \u00e7e\u015fitli finansman mekanizmalar\u0131n\u0131 desteklemektedir.<\/span><\/p>\n

Bug\u00fcne kadar EE, d\u00fcnyan\u0131n d\u00f6rt bir yan\u0131ndan \u00e7ok disiplinli ekibe milyonlarca dolar hibe etmi\u015f ve takip eden fonlarda milyonlarca dolar\u0131n daha g\u00fcvence alt\u0131na al\u0131nmas\u0131na yard\u0131mc\u0131 olmu\u015ftur. Verilen hibeleri incelemek i\u00e7in ziyaret edin <\/span>https:\/\/www.emilysentourage.org\/awarded-grants\/<\/span><\/a>. EE'nin finansman f\u0131rsatlar\u0131 hakk\u0131nda daha fazla bilgi edinmek i\u00e7in \u015fu adresi ziyaret edin <\/span>https:\/\/www.emilysentourage.org\/funding-opportunities\/<\/span><\/a>.<\/span><\/p>\n

Emily'nin \u00c7evresi Hakk\u0131nda<\/b><\/p>\n

Emily\u2019s Entourage (EE), mevcut mutasyona y\u00f6nelik tedavilerden fayda g\u00f6remeyen kistik fibroz (CF) hastalar\u0131n\u0131n son a\u015famas\u0131ndaki bireyler i\u00e7in yeni tedaviler ve bir \u00e7are bulunmas\u0131na y\u00f6nelik ara\u015ft\u0131rmalar\u0131 h\u0131zland\u0131ran yenilik\u00e7i bir 501(c)(3) kurulu\u015fudur. 2011 y\u0131l\u0131ndan bu yana EE, milyonlarca dolarl\u0131k ara\u015ft\u0131rma hibesi vermi\u015f, klinik a\u015famada bir CF gen terapisi \u015firketi kurmu\u015f, klinik denemelere kat\u0131l\u0131m\u0131 h\u0131zland\u0131rmak i\u00e7in k\u00fcresel bir hasta veritaban\u0131 ve klinik deneme e\u015fle\u015ftirme program\u0131 geli\u015ftirmi\u015f ve y\u00fcksek etkili ara\u015ft\u0131rma ve ila\u00e7 geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131n\u0131 te\u015fvik etmek amac\u0131yla d\u00fcnya \u00e7ap\u0131nda giri\u015fimlere \u00f6nc\u00fcl\u00fck etmi\u015ftir. Kurulu\u015f, New York Times, STAT, CNN, People ve daha fazlas\u0131 dahil olmak \u00fczere ulusal medyada yer alm\u0131\u015ft\u0131r. Daha fazla bilgi i\u00e7in<\/span> emilysentourage.org<\/span><\/a>.<\/span><\/p>\n

Medya \u0130leti\u015fim<\/b><\/p>\n

Hannah Kleckner<\/span><\/p>\n

Pazarlama ve \u0130leti\u015fim Direkt\u00f6r\u00fc<\/span><\/p>\n

hannah@emilysentourage.org\u00a0

<\/p>","protected":false},"excerpt":{"rendered":"

Inhaled vancomycin\u2013DNase combination aims to overcome biofilms and improve treatment for persistent MRSA infections Lower Merion, PA\u2014August 24, 2026\u2014Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating research for individuals with cystic fibrosis (CF) who do not benefit from current mutation-targeted therapies, today announced its third\u00a02026 Translational Research Grant awarded to Hugh Smyth, PhD, Alcon Centennial… <\/p>\n

<\/div>\n

Daha fazla bilgi edinin<\/a><\/p>","protected":false},"author":1719,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"","_seopress_redirections_param":"","_seopress_redirections_type":0,"_seopress_analysis_target_kw":"","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[178],"tags":[197,272,223,216,204],"class_list":["post-27060","post","type-post","status-publish","format-standard","hentry","category-press-releases","tag-cf-research","tag-cf-research-grant","tag-ee-grant","tag-ee-grants","tag-ee-research"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/27060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/users\/1719"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/comments?post=27060"}],"version-history":[{"count":4,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/27060\/revisions"}],"predecessor-version":[{"id":27065,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/27060\/revisions\/27065"}],"wp:attachment":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/media?parent=27060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/categories?post=27060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/tags?post=27060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}